JP2016518379A - Ｏｂフォールド変異体を含む局所用組成物 - Google Patents

Ｏｂフォールド変異体を含む局所用組成物 Download PDF

Info

Publication number
JP2016518379A
JP2016518379A JP2016509434A JP2016509434A JP2016518379A JP 2016518379 A JP2016518379 A JP 2016518379A JP 2016509434 A JP2016509434 A JP 2016509434A JP 2016509434 A JP2016509434 A JP 2016509434A JP 2016518379 A JP2016518379 A JP 2016518379A
Authority
JP
Japan
Prior art keywords
agent
composition according
skin
protein
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016509434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518379A5 (enExample
Inventor
オリビエ キッテン
オリビエ キッテン
Original Assignee
アフィロジック
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アフィロジック filed Critical アフィロジック
Publication of JP2016518379A publication Critical patent/JP2016518379A/ja
Publication of JP2016518379A5 publication Critical patent/JP2016518379A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
JP2016509434A 2013-04-22 2014-04-22 Ｏｂフォールド変異体を含む局所用組成物 Pending JP2016518379A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR13/53662 2013-04-22
FR1353662A FR3004650B1 (fr) 2013-04-22 2013-04-22 Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
PCT/EP2014/058139 WO2014173899A1 (fr) 2013-04-22 2014-04-22 Compositions topiques comprenant des variantes de pli-ob

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019022358A Division JP2019112410A (ja) 2013-04-22 2019-02-12 Ｏｂフォールド変異体を含む局所用組成物

Publications (2)

Publication Number Publication Date
JP2016518379A true JP2016518379A (ja) 2016-06-23
JP2016518379A5 JP2016518379A5 (enExample) 2017-06-15

Family

ID=48795734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016509434A Pending JP2016518379A (ja) 2013-04-22 2014-04-22 Ｏｂフォールド変異体を含む局所用組成物
JP2019022358A Pending JP2019112410A (ja) 2013-04-22 2019-02-12 Ｏｂフォールド変異体を含む局所用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019022358A Pending JP2019112410A (ja) 2013-04-22 2019-02-12 Ｏｂフォールド変異体を含む局所用組成物

Country Status (7)

Country Link
US (2) US10548945B2 (enExample)
EP (1) EP2988766B1 (enExample)
JP (2) JP2016518379A (enExample)
CN (2) CN111467477A (enExample)
ES (1) ES2637421T3 (enExample)
FR (1) FR3004650B1 (enExample)
WO (1) WO2014173899A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502823A (ja) * 2017-11-14 2021-02-04 アフィロジック 多重特異性分子

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
FR3027521B1 (fr) * 2014-10-24 2016-12-16 Affilogic Compositions pour administration par voie orale
EP3632924A1 (en) 2018-10-07 2020-04-08 Affilogic Binders for inhibiting formation of multimeric proteins
WO2020231504A1 (en) 2019-05-16 2020-11-19 Massachusetts Institute Of Technology Glycan-binding proteins and related compositions and methods
EP3878858A1 (en) 2020-03-11 2021-09-15 Affilogic Variants of sac7d and their use in cancer therapy
EP4043481A1 (en) 2021-02-15 2022-08-17 Affilogic Compounds and methods for extending half life of biomolecules
JP2024513711A (ja) 2021-03-18 2024-03-27 アフィロジック 抗ｃ３因子ｓａｃ７ｄバリアントおよびその補体介在性障害を治療するための医学的使用
EP4059949A1 (en) 2021-03-18 2022-09-21 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
CN117106745B (zh) * 2022-06-01 2025-02-14 北京擎科生物科技股份有限公司 逆转录突变体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010511691A (ja) * 2006-12-04 2010-04-15 インスティティ・パスツール 新たな特異的結合体を工学的に操作するための足場として使用されるｏｂ−フォールド

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228616A1 (en) * 1999-10-29 2003-12-11 Stratagene DNA polymerase mutants with reverse transcriptase activity
EP2029620B1 (en) * 2006-05-26 2016-05-25 Waikatolink Limited Ob fold domains
ES2836948T3 (es) * 2008-11-03 2021-06-28 Molecular Partners Ag Proteínas de unión que inhiben la interacción del receptor de VEGF-A
US20110098216A1 (en) * 2009-10-22 2011-04-28 Regen Therapeutics Plc Therapeutic uses of colostrinin
EP2469278A1 (en) * 2010-12-21 2012-06-27 Institut Pasteur Reagentless fluorescent biosensors from nanofitins, rational design methods to create reagentless fluorescent biosensors and methods of their use
FR2974816A1 (fr) * 2011-05-04 2012-11-09 Centre Nat Rech Scient Methode de generation de proteines
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
FR3027521B1 (fr) * 2014-10-24 2016-12-16 Affilogic Compositions pour administration par voie orale
PL412787A1 (pl) * 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
US20190167576A1 (en) * 2016-09-08 2019-06-06 The Board Of Trustees Of The Leland Stanford Junior University Use of high affinity monoclonal antibody product binders to increase the duration of action of therapeutic monoclonal antibody products in a biologic tissue
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules
EP3632924A1 (en) * 2018-10-07 2020-04-08 Affilogic Binders for inhibiting formation of multimeric proteins
EP3878858A1 (en) * 2020-03-11 2021-09-15 Affilogic Variants of sac7d and their use in cancer therapy
EP4059949A1 (en) * 2021-03-18 2022-09-21 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010511691A (ja) * 2006-12-04 2010-04-15 インスティティ・パスツール 新たな特異的結合体を工学的に操作するための足場として使用されるｏｂ−フォールド

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MEMBRANE, vol. 36, no. 4, JPN6019017366, 2011, pages 139 - 144, ISSN: 0004034783 *
PLOS ONE, JPN6019017365, 2015, pages 1 - 17, ISSN: 0004034782 *
日経バイオテクONLINE, vol. [平成２９年１２月１８日検索], JPN6017049770, February 2013 (2013-02-01), ISSN: 0004034781 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502823A (ja) * 2017-11-14 2021-02-04 アフィロジック 多重特異性分子

Also Published As

Publication number Publication date
WO2014173899A1 (fr) 2014-10-30
CN105338995B (zh) 2020-06-09
FR3004650A1 (fr) 2014-10-24
US10898542B2 (en) 2021-01-26
FR3004650B1 (fr) 2015-05-29
ES2637421T3 (es) 2017-10-13
CN111467477A (zh) 2020-07-31
US10548945B2 (en) 2020-02-04
US20160143990A1 (en) 2016-05-26
JP2019112410A (ja) 2019-07-11
US20200138899A1 (en) 2020-05-07
EP2988766B1 (fr) 2017-06-07
EP2988766A1 (fr) 2016-03-02
CN105338995A (zh) 2016-02-17

Similar Documents

Publication Publication Date Title
US10898542B2 (en) Topical compositions comprising OB-fold variants
Jiang et al. Bioinspired design of mannose-decorated globular lysine dendrimers promotes diabetic wound healing by orchestrating appropriate macrophage polarization
KR20160113121A (ko) 핵산 제조 및 송달을 위한 방법 및 산물
JP2015517995A (ja) 美容タンパク質およびペプチドの産生のための修飾ポリヌクレオチド
EP3808762A1 (en) Fusion protein bound to cell-permeable peptide, and composition comprising fusion protein or cell-permeable peptide and epithelial cell growth factor as active ingredients
US8734775B2 (en) Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
KR20110131187A (ko) 여드름 및 기타 질환 치료용 비스파틴 치료제
CN1879888B (zh) 透皮给药增强剂及其使用方法
CN118515761B (zh) 一种gdf-15纳米抗体及其应用
CN112135636A (zh) 含有核酸复合物的皮肤渗透载体及其用途
CN118307663A (zh) 具有三螺旋结构的重组ⅹⅶ型胶原蛋白及其应用
CA2896939C (en) Treatment of hyperhidrosis
CN112423780A (zh) 通过靶向集落刺激因子进行的青光眼和视神经病变的治疗
US20230137756A1 (en) Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19
WO2015086830A1 (en) Skin penetrating polypeptides
WO2019047299A1 (zh) 具有核定位能力的透皮短肽及其应用
US20190030186A1 (en) Use of bacterial voltage gated ion channels for human therapies
CN102603887B (zh) 一种具有抗瘤活性的il-24多肽及其应用
EP1334195B1 (de) Analoga, agonisten, antagonisten und varianten der oxidoreduktase-enzymaktivität des makrophagen-migrations-inhibitions-faktors (mif) als immunmodulatoren, therapeutika, diagnostika und screening-agenzien bei inflammatorischen und immunerkrankungen
KR101626758B1 (ko) 피부 투과성을 갖는 인간 염기성 섬유아세포 성장인자의 개발, 생산 및 화장품 조성물
RU2688422C1 (ru) Рекомбинантный интерналин В 321, полученный с помощью штамма Escherichia coli
JP2005298371A (ja) アンタゴニストポリペプチド
WO2025241119A1 (zh) 融合蛋白及其应用
KR20250169359A (ko) 성장인자인 fgf 및 scf를 전달하는 세포 투과성 펩타이드 및 이의 상처 치유용 조성물
CN120818018A (zh) Fga来源12肽在制备神经损伤修复药物中的用途

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190320

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190322

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190517